Quarterly ResultMay 12, 2026, 04:07 PM
TriSalus Q1 Revenue $8.9M; Net Income $1.5M; Revises 2026 Guidance
AI Summary
TriSalus Life Sciences reported Q1 2026 revenue of $8.9 million, a 2.9% decrease year-over-year, primarily due to commercial expansion efforts. Despite increased operating losses, the company achieved a net income of $1.5 million, significantly up from a net loss of $11.1 million in Q1 2025, largely driven by non-cash gains from derivative changes. TriSalus also strengthened its balance sheet with a $46 million equity raise, bringing its cash balance to $56.6 million, and revised its 2026 revenue guidance to $54 million to $57 million, reflecting commercial expansion impact and delayed FDA clearance for TriNav Advance.
Key Highlights
- Generated Q1 2026 revenue of $8.9 million, a 2.9% decrease from Q1 2025.
- Reported Q1 2026 net income of $1.5 million, compared to a net loss of $11.1 million in Q1 2025.
- Achieved basic and diluted EPS of $0.03 for Q1 2026, up from $(0.39) in Q1 2025.
- Strengthened balance sheet with a $46 million equity raise, ending Q1 with $56.6 million cash.
- Revised 2026 revenue guidance to $54 million to $57 million.
- Published a real-world PEDD® Study showing fewer complications and $7,700 per-patient charge avoidance.
- Appointed Michael P. Stansky to the Board and Richard Marshall, M.D., as Chief Medical Officer.